Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Subscribe To Our Newsletter & Stay Updated